MedTrace Logo

AZD9833 China PK Study

NCT04818632 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-12-17

No results posted yet for this study

Summary

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Chinese patients with ER Positive, HER2 Negative, Metastatic Breast Cancer

Conditions

  • ER+, HER2-, Metastatic Breast Cancer

Interventions

DRUG

AZD9833

Part A: AZD9833 monotherapy dose escalation.

DRUG

AZD9833

Part B: AZD9833 monotherapy dose expansion

DRUG

AZD9833 with palbociclib

Part B: AZD9833 with palbociclib dose expansion

DRUG

AZD9833 with everolimus

Part B: AZD9833 with everolimus dose expansion

Sponsors & Collaborators

Principal Investigators

  • Jiong Wu · Department of Breast Surgery, Fudan University Shanghai Cancer Center

  • Jian Zhang · Department of Medical Oncology, Fudan University Shanghai Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-12
Primary Completion
2023-09-07
Completion
2023-09-07

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04818632 on ClinicalTrials.gov